Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF) Stock Short Interest Report for September

Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 1,378,001 shares, a decrease of 56.5% from the September 15th total of 3,166,158 shares. Based on an average daily trading volume, of 43,882 shares, the short-interest ratio is currently 31.4 days.

Analysts Set New Price Targets

Separately, Jefferies Financial Group cut Kyowa Kirin to a “hold” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Kyowa Kirin Stock Performance

OTCMKTS KYKOF opened at $13.90 on Tuesday. Kyowa Kirin has a 12 month low of $4.20 and a 12 month high of $15.90. The company’s 50 day simple moving average is $14.72 and its 200 day simple moving average is $14.40.

Kyowa Kirin Company Profile

Kyowa Kirin Co, Ltd. is a Japan-based specialty pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses on therapies for areas including oncology, immunology, nephrology, the central nervous system and rare diseases, with an emphasis on biologics and other innovative treatments.

Its products include Poteligeo (mogamulizumab), an antibody used in certain hematologic cancers and cutaneous T-cell lymphomas, and Crysvita (burosumab), a treatment for disorders involving abnormal phosphate regulation.